Search All UT System Experts

Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2

Hidekazu Tanaka, Michinari Hirata, Satomi Shinonome, Toru Wada, Motofumi Iguchi, Keiji Dohi, Makiko Inoue, Yukichi Ishioka, Kanji Hojo, Tomomi Yamada, Tatsuya Sugimoto, Koichi Masuno, Ken ichi Nezasa, Norihito Sato, Kenji Matsuo, Shuji Yonezawa, Eugene P. Frenkel, Michitaka Shichijo

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Fingerprint

Dive into the research topics of 'Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2'. Together they form a unique fingerprint.

Medicine & Life Sciences